dibenz(a,h)anthracene-3,4-diol 1,2-oxide: structure given in first source; RN refers to (1a alpha,2 beta,3 alpha,13c alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 119527 |
| MeSH ID | M0213062 |
| Synonym |
|---|
| dbade |
| 70951-81-4 |
| naphtho(2',1':6,7)phenanthro(3,4-b)oxirene-2,3-diol, 1a,2,3,13c-tetrahydro-, (1aalpha,2beta,3alpha,13calpha)- |
| dibenz(a,h)anthracene-3,4-diol-1,2-epoxide |
| anti-3,4-dihydroxy-1,2-epoxy-1,2,3,4-tetrahydrodibenz(a,h)anthracene |
| dba 3,4-diol 1,2-oxide |
| (1aalpha,2beta,3alpha,13calpha)-1a,2,3,13c-tetrahydro-naphtho(2',1':6,7)phenanthro(3,4-b)oxirene-2,3-diol |
| anti-dibenz(a,h)anthracene-3,4-dihydrodiol-1,2-oxide |
| dibenz(a,h)anthracene-3,4-diol 1,2-oxide |
| db(a,h)a-3,4-diol 1,2-oxide |
| DTXSID60991243 |
| 1a,2,3,13c-tetrahydrobenzo[8,9]tetrapheno[1,2-b]oxirene-2,3-diol |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||